Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2026

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

• Nucleic Acid And Gene Therapies In Neuromuscular Disorders market size has reached to $7.5 billion in 2025 • Expected to grow to $11.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Prevalence Of Genetic Disorders Fuels Growth In The Market • Market Trend: Advancements In Gene Therapy For Neuromuscular Disorders • North America was the largest region in 2025.

What Is Covered Under Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Nucleic acid and gene therapies in neuromuscular disorders refer to innovative treatments that aim to correct or compensate for the genetic mutations underlying these diseases. Neuromuscular disorders (NMDs) are conditions that affect the muscles and nerves, often due to inherited genetic mutations. These therapies involve the use of nucleic acids or genetic material to repair, replace, or modulate gene expression, thereby addressing the root cause of the disorder. The main disorders in nucleic acid and gene therapies in neuromuscular disorders are motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies including muscular dystrophies. Motor neuron diseases refer to a group of progressive neurological disorders that affect motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. The therapies include adeno-associated viruses gene therapy, postnatal gene therapy, and spinal muscular atrophy. The various applications include hospitals, specialty clinics, and ambulatory surgery centers.

What Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Forecast?

The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $11.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in adeno-associated virus and postnatal gene therapies, increasing r&d investments in nmds, growing number of hospitals and specialty clinics offering gene therapies, rising prevalence of neuromuscular disorders, increasing patient awareness and advocacy initiatives. Major trends in the forecast period include rising adoption of gene therapy techniques, increasing development of nucleic acid therapeutics, growing focus on rare neuromuscular disorders, rising investment in personalized medicine approaches, increasing integration of advanced diagnostic and monitoring tools.

What Is The Driver Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The increasing prevalence of genetic disorders is expected to propel the growth of the nucleic acid and gene therapies in neuromuscular disorders market going forward. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either inherited or resulting from mutations. The increase in genetic disorders is due to factors such as genetic mutations, environmental influences, lifestyle changes, and improved diagnostic capabilities. Nucleic acid and gene therapies help genetic disorders by correcting or replacing defective genes in neuromuscular conditions to restore normal function. For instance, in May 2024, according to Cure SMA, a US-based non-profit organization, In the United States, approximately 9,000 to 9,500 individuals are currently living with Spinal Muscular Atrophy (SMA). Among the total population, 37% have Type 2 SMA. The condition has an estimated incidence rate of 1 in 15,000 births. Therefore, the increasing prevalence of genetic disorders is driving the growth of the nucleic acid and gene therapies in neuromuscular disorders industry.

Key Players In The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends and Insights

Major companies are operating in the nucleic acid and gene therapies in neuromuscular disorders market, focusing on developing innovative therapies such as gene therapy to address the root causes of genetic neuromuscular conditions through targeted gene correction or replacement. Gene therapy refers to the treatment of diseases by introducing, altering, or repairing genetic material within a patient's cells to correct or replace defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. The therapy is administered as a single intravenous infusion, simplifying the treatment process compared to other therapies that may require ongoing infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is essential for muscle function. This innovative approach addresses the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, thereby potentially halting or reversing disease progression.

What Are Latest Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. With this acquisition, Novartis aims to enhance its gene therapy capabilities for inherited neuromuscular diseases by integrating AAV-based gene therapy platform DELIVER and preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy and myotonic dystrophy type 1 into its portfolio. Kate Therapeutics Inc. is a US-based biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases.

What Defines the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2026?

The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.